Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

FDA opens Cleveland BioLabs' IND for CBLB-502

Oct. 20, 2011

Viralytics begins enrollment in phase II Cavatak trial following approval for dosing

Oct. 20, 2011

New protein kinase inhibitors presented by GSK

Oct. 20, 2011

Phase II study assessed combination therapy containing rilotumumab in cancer

Oct. 20, 2011

Vandetanib/bicalutamide combination trial does not meet primary endpoint

Oct. 20, 2011

BeiGene in-licenses two clinical-stage oncology candidates

Oct. 20, 2011

New carbazole-linked hybrid antitumor agents prepared

Oct. 20, 2011

Lilly begins phase II study of LY-2510924 in SCLC

Oct. 20, 2011

CSIR presents new antitumor agents

Oct. 19, 2011

Novel B-raf inhibitors disclosed by Boehringer Ingelheim

Oct. 19, 2011

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Fauci’s silence may put him in contempt of Congress
BioWorld
After repeatedly invoking the Fifth Amendment to every question asked during the July 29 hearing of the U.S. Senate Homeland Security Committee, Anthony Fauci,...